The Influence of Age on Complications and Overall Survival After Ivor Lewis Totally Minimally Invasive Esophagectomy

Nikolaj S. Baranov 1 · Frans van Workum 1 · Jolijn van der Maas 2 · Ewout Kouwenhoven 2 · Marc van Det 2 · Frits J. H. van den Wildenberg 3 · Fatih Polat 3 · Grard A. P. Nieuwenhuijzen 4 · Misha D. P. Luyer 4 · Camiel Rosman 1

Received: 29 September 2018 / Accepted: 15 November 2018 / Published online: 18 December 2018
© 2018 The Author(s)

Abstract

Background The number of elderly patients suffering from esophageal cancer is increasing, due to an increasing incidence of esophageal cancer and increasing life expectancy. However, the effect of age on morbidity, mortality, and survival after Ivor Lewis total minimally invasive esophagectomy (TMIE) is not well known.

Methods A prospectively documented database from December 2010 to June 2017 was analyzed, including all patients who underwent Ivor Lewis TMIE for esophageal cancer in three Dutch high-volume esophageal cancer centers. Patients younger than 75 years (younger group) were compared to patients aged 75 years or older (elderly group). Baseline patient characteristics and perioperative data were included. Surgical complications were graded using the Clavien-Dindo scale. The primary outcome was postoperative complications Clavien-Dindo ≥ 3. Secondary outcome parameters were postoperative complications, in-hospital mortality, 30- and 90-day mortality and survival.

Results Four hundred and forty-six patients were included, 357 in the younger and 89 in the elderly group. No significant differences were recorded regarding baseline patient characteristics. There was no significant difference in complications graded Clavien-Dindo ≥ 3 and overall complications, short-term mortality, and survival. Delirium occurred in 27.0% in the elderly and 11.8% in the younger group (p < 0.001). After correction for baseline comorbidity this difference remained significant (p = 0.001). Median hospital length of stay was 13 days in the elderly and 11 days in the younger group (p = 0.010).

Conclusions Ivor Lewis TMIE can be safely performed in selected elderly patients without increasing postoperative morbidity and mortality.

Keywords Esophageal neoplasms · Esophagectomy · Aged · Postoperative complications · Mortality

Introduction

The incidence of esophageal cancer is increasing, with a current incidence of 455,000 worldwide.1 The number of elderly patients diagnosed with esophageal cancer is increasing mainly due to an increased life expectancy of the general population. Esophageal resection with gastric conduit reconstruction after neoadjuvant therapy is the treatment of choice for patients with resectable esophageal carcinoma.2, 3 Esophagectomy is associated with considerable morbidity and mortality and this might be higher for elderly patients since they are more frail and generally have more comorbidities than younger patients.4, 5

Previous studies focusing on age-related morbidity and mortality regarding esophagectomy included patients that had been treated with open esophageal resection and showed that elderly patients have an increased peri-operative and in-hospital mortality risk, developed more postoperative complications, and have a higher rate of complications requiring reoperation.6, 7
complications and ultimately are confronted with a decreased 5-year survival rate.\(^6,7\) Other studies, however, show no significant differences regarding short-term mortality and survival.\(^8,9\) Nonetheless, most of these studies were single-center experiences, reported on small numbers of patients, included heterogeneous surgical approaches and very few underwent minimally invasive esophagectomy.\(^6–9\) Both a total minimally invasive esophagectomy (TMIE) and an Ivor Lewis approach have been shown to be associated with less postoperative morbidity compared with an open esophagectomy and a McKeown approach.\(^10–12\) Several studies regarding colon cancer have shown that laparoscopic assisted colectomy is associated with less postoperative morbidity when compared to open colectomy in elderly patients.\(^13,14\) However, it is currently unknown whether or not a minimal invasive Ivor Lewis esophagectomy is also associated with acceptable morbidity for older patients.

Therefore, the objective of this study was to analyze the influence of age on short- and long-term outcomes after Ivor Lewis TMIE.

**Material and Methods**

**Patients**

All patients with esophageal carcinoma undergoing elective Ivor Lewis TMIE with curative intent were included. Patients aged \(\geq 75\) years (elderly group) were compared with patients < 75 years (younger group). The cutoff value of 75 years was chosen, because patients aged \(\geq 75\) years are generally excluded from clinical trials (including the TIME and MIRO trial).\(^16\) Patients were operated on in three high-volume esophageal cancer centers in the Netherlands (Canisius-Wilhelmina hospital Nijmegen, Catharina hospital Eindhoven and ZGT hospital Almelo) from December 2010 to June 2017.

**Study Design**

The three participating hospitals entered data of all esophageal cancer patients undergoing surgery into a prospective database. Data on patient-, tumor-, and operative characteristics, neoadjuvant treatment, postoperative complications, length of hospital and ICU stay, readmissions, postoperative mortality, pathology results, and overall survival were retrospectively analyzed.

**Outcome Parameters**

The primary outcome parameter was complications graded \(\geq III\) according to the Clavien-Dindo (CD) classification.\(^15\) Secondary outcome parameters were the associated failure to rescue (FTR), CD complications graded < II, in-hospital mortality, 30- and 90-day mortality, failure to rescue, and long-term survival.

**Definitions**

Postoperative complications studied were pulmonary complications, cardiac complications, and other specified complications. Pulmonary complications were defined as the combined incidence of pneumothorax, pleural empyema, pleural effusion, a small group of other, less frequently diagnosed pulmonary complications called “other pulmonary complications,” and clinically diagnosed pneumonia defined according to the revised Uniform Pneumonia Score (r-UPS) for which treatment was started.\(^16\) Cardiac complications included atrial fibrillation, myocardial infarction, asystoly, and pericarditis, diagnosed by electrocardiogram, ultrasound, and/or laboratory findings. To account for cardiac complications that were not listed, and which are not as frequently diagnosed, those complications were combined in a small group of “other cardiac complications.” Other postoperative complications that were recorded included anastomotic leakage defined according to the Esophageal Complications Consensus Group (ECCG),\(^17\) delirium, jejunostomy (JJS)-related complications, urinary tract infection (UTI), urine retention, thrombo-embolic (TE) events, cerebrovascular accidents (CVA), chylothorax, and bronchoesophageal (BE) fistula.

Complications that could be directly attributed to the specific surgical process of an esophagectomy were considered to be “technical” and consisted of anastomotic leakage, chylothorax, and BE fistula. More general complications, occurring during hospital stay, were defined as “clinical” complications and included pulmonary complications, cardiac complications, delirium, CVA, UTI/urine retention, and TE events. In hospital, mortality was defined as any death occurring during hospital admittance. In addition, the 30-day, 90-day mortality, 1-year, and 2-year survival rates were analyzed.

**Operative Technique**

Ivor Lewis TMIE consisted of laparothoracoscopic resection with intrathoracic esophagogastronomy.\(^18\) Three types of intrathoracic anastomosis were used: 1) a linear stapled side-to-side (S-S) anastomosis, 2) a circular stapled end-to-side (E-S) anastomosis, or a handsewn end-to-end (E-E) anastomosis.

**Statistical Analysis**

Statistical analysis was performed with the SPSS software package, version 24.0 (SPSS Inc., IBM Corporation Software Group, Somers, NY, USA). For dichotomous or ordinal variables, the Pearson’s chi-square test or Fisher’s exact test was used when appropriate. For non-normally distributed data, the Mann-Whitney \(U\) test was used. All tests were two-
| Table 1 Patient characteristics | Patients < 75 years N = 357 (%) | Patients ≥ 75 years N = 89 (%) | p value |
|--------------------------------|----------------------------------|---------------------------------|---------|
| Hospital                       |                                  |                                 | 0.041   |
| –1                             | 148 (41.5%)                      | 32 (36.0%)                      |         |
| –2                             | 163 (45.7%)                      | 36 (40.4%)                      |         |
| –3                             | 46 (12.9%)                       | 21 (23.6%)                      |         |
| BMI                            |                                  |                                 | 0.158   |
| –Median/IQR                    | 25.7 (5.4)                       | 24.7 (3.8)                      |         |
| Age                            |                                  |                                 | < 0.001 |
| 0.158median/IQR                | 63.5 (10.3)                      | 75.9 (3.3)                      | 0.625   |
| Sex                            |                                  |                                 | 0.625   |
| –Male                          | 293 (82.1%)                      | 75 (84.3%)                      |         |
| –Female                        | 64 (17.9%)                       | 14 (15.7%)                      |         |
| ASA classification             |                                  |                                 | 0.063   |
| –1                             | 42 (11.8%)                       | 5 (5.6%)                        |         |
| –2                             | 293 (66.9%)                      | 56 (62.9%)                      |         |
| –3                             | 73 (20.4%)                       | 28 (31.5%)                      |         |
| –4                             | 3 (0.8%)                         | 0 (0.0%)                        |         |
| Charlson Co-morbidity Index score (three groups) | | | 0.058 |
| –0                             | 202 (56.6%)                      | 38 (42.7%)                      |         |
| –1                             | 90 (25.2%)                       | 28 (31.5%)                      |         |
| –≥2                            | 65 (18.2%)                       | 23 (25.8%)                      |         |
| Neoadjuvant therapy            |                                  |                                 | 0.584   |
| –Chemoradiotherapy             | 331 (92.7%)                      | 80 (89.9%)                      |         |
| –Chemotherapy                  | 8 (2.2%)                         | 2 (2.2%)                        |         |
| –Radiotherapy                  | 0 (0.0%)                         | 0 (0.0%)                        |         |
| –None                          | 18 (5.0%)                        | 7 (7.9%)                        |         |
| Tumor stage                    |                                  |                                 | 0.845*  |
| –I                             | 96 (26.9%)                       | 25 (28.1%)                      |         |
| –II                            | 160 (44.8%)                      | 40 (44.9%)                      |         |
| –III                           | 101 (28.3%)                      | 22 (24.7%)                      |         |
| –IV                            | 0 (0.0%)                         | 0 (0.0%)                        |         |
| Tumor type                     |                                  |                                 | 0.083   |
| –SCC                           | 49 (13.7%)                       | 9 (10.1%)                       |         |
| –Adenocarcinoma                | 300 (84.0%)                      | 78 (87.6%)                      |         |
| –Other                         | 7 (2.0%)                         | 0 (0.0%)                        |         |
| –Unable to specify             | 1 (0.3%)                         | 2 (2.2%)                        |         |
| Tumor location                 |                                  |                                 | 0.239   |
| –Mid esophagus                 | 25 (7.0%)                        | 4 (4.5%)                        |         |
| –Distal esophagus              | 253 (70.9%)                      | 71 (79.8%)                      |         |
| –Junction                      | 79 (22.1%)                       | 14 (15.7%)                      |         |
| Anastomotic configuration      |                                  |                                 | 1.000   |
| –End to end                    | 4 (1.1%)                         | 1 (1.1%)                        |         |
| –End to side                   | 177 (49.6%)                      | 44 (49.4%)                      |         |
| –Side to side                  | 176 (49.3%)                      | 44 (49.4%)                      |         |
| Anastomotic technique          |                                  |                                 | 0.170   |
| –Handsewn                      | 31 (8.7%)                        | 12 (13.5%)                      |         |
| –Stapled                       | 326 (91.3%)                      | 77 (86.5%)                      |         |

*Patients from whom clinical stage could not be assessed were excluded. Total: 2
 sided, and p values less than 0.05 were considered to be statistically significant. Binominal logistic regression analysis was used when differences in case mix parameters between the groups were associated with p values of < 0.1, to adjust for bias from differences in baseline patient characteristics. The Kaplan-Meier method was used to estimate the 1- and 2-year survival, with the Mantel-Cox log-rank test to determine whether there were statistically significant differences between the groups. In addition to the main analysis, hospital length of stay (LOS) was compared between elderly and younger patients in a subgroup that experienced complications and a subgroup that experienced severe complications, to evaluate whether there were any differences in how patients recover from complications.

**Results**

Some 446 patients were enrolled and analyzed. Three hundred and fifty-seven patients were younger than 75 years (younger group) and 89 patients were aged 75 years and older (elderly group).

**Patient and Operation Characteristics**

There was a trend towards a higher CCI score in the elderly group (p = 0.058, Table 1). ASA III tended to be higher in the elderly group (p = 0.063, Table 1). Other patient characteristics and operation characteristics did not differ significantly between the groups (Table 1 and Table 2).

**Postoperative Outcome Parameters**

Postoperative complications are shown in Table 3. There was no significant difference between the younger group and the elderly group regarding severe complications (35.9% in the younger group versus 43.8% in the elderly group, p = 0.421). Regarding the associated FTR, the younger group (8.6%) and the elderly group (11.1%) did not significantly differ (p = 0.743). The incidence of overall complications was 72.8% in the younger group versus 79.8% in the elderly group (p = 0.180). The incidence of technical complications was 24.6% in the younger group and 25.8% in the elderly group (p = 0.816) and clinical complications (69.7% versus 76.4%; p = 0.215). The incidence of cardiovascular complications was higher in the elderly group (14.0% versus 24.7%; p = 0.014). Other complications, reoperation rate, reintervention rate, and (ICU) length of stay did not significantly differ between the two groups. The incidence of postoperative delirium was 27% in the elderly group and 11.8% in the younger group (p < 0.001). These differences persisted in binary logistic regression analyses correcting for comorbidity and ASA score. In addition, median hospital length of stay (LOS) was significantly shorter in the younger group than in the elderly group (11 versus 13 days, p = 0.010).

In both a subset of patients that experienced postoperative complications and a subset of patients that experienced severe complications, the median hospital LOS did not differ significantly between the elderly group and the younger group.

**Mortality and Survival**

In-hospital mortality was 3.1% in the younger group versus 3.4% in the elderly group (p = 0.513) and 30-day mortality was 2.8% in the younger group versus 2.2% in the elderly group (p = 0.889). Ninety-day mortality was 5.0% in the younger group versus 9.0% in the elderly group (p = 0.155) (Table 4).

One-year survival was 77.9% in the younger group versus 76.4% in the elderly group (p = 0.767) and 2-year survival was 54.5% in the younger group and 57.3% in the elderly group (p = 0.666) (Fig. 1).

*Table 2 Operation and pathology characteristics*

|                        | Patients < 75 years N=357 (%) | Patients ≥ 75 years N=89 (%) | p value |
|------------------------|-------------------------------|-------------------------------|---------|
| Abdominal conversion   | 7 (2.0%)                      | 3 (3.4%)                      | 0.425   |
| Thoracic conversion    | 8 (2.2%)                      | 3 (3.4%)                      | 0.465   |
| Operation time (min)   |                               |                               |         |
| –Median/IQR            | 252 (85)                      | 278 (100)                     | 0.064   |
| Peri-operative blood loss (mL) |         |                               |         |
| –Median/IQR            | 100 (120)                     | 100 (100)                     | 0.938*  |
| Lymph nodes            |                               |                               |         |
| –Median/IQR            | 21 (11)                       | 20 (9)                        | 0.424   |
| R0-resection           | 340 (95.2%)                   | 81 (91%)                      | 0.121   |
| Complete pathological response | 60 (16.8%) | 16 (18.0%)                   | 0.793   |

*Patients from whom blood loss could not be assessed were excluded. Total: 18, 2 from the elderly group and 16 from the younger group*
| Complication                  | Patients < 75 years | p value | Adjusted p value* | Odds (95%-BI)     |
|-------------------------------|---------------------|---------|-------------------|-------------------|
| **Severe complications (CD ≥ 3)** |                     |         |                   |                   |
| - FTR**                       | 11 (8.6)            | 0.421   | 0.625             | 1.13 (0.70, 1.83) |
| Anastomotic leakage           | 61 (17.1)           | 0.654   | 0.715             | 1.12 (0.61, 2.03) |
| - Grade 1                     | 5 (1.4)             | 0.201   | 0.256             | 2.32 (0.54, 9.95) |
| - Grade 2                     | 33 (9.2)            | 0.941   | 0.881             | 0.94 (0.42, 2.12) |
| - Grade 3                     | 23 (6.4)            | 0.918   | 0.899             | 1.06 (0.42, 2.70) |
| Chyle leakage                 | 29 (8.1)            | 0.936   | 0.940             | 0.97 (0.41, 2.29) |
| **Pulmonary complications**   |                     |         |                   |                   |
| - Pneumonia                   | 117 (32.8)          | 0.813   | 0.678             | 0.90 (0.54, 1.49) |
| - Empyema                     | 42 (11.8)           | 0.889   | 0.863             | 0.94 (0.45, 1.96) |
| - Pneumothorax                | 58 (16.2)           | 0.364   | 0.320             | 0.70 (0.35, 1.41) |
| - Pleural effusion            | 93 (26.1)           | 0.546   | 0.550             | 1.17 (0.70, 1.96) |
| - Other                       | 68 (19.0)           | 0.991   | 0.964             | 0.99 (0.55, 1.79) |
| Cardiac complications         |                     |         |                   |                   |
| - AF                          | 41 (11.5)           | 0.056   | 0.063             | 1.81 (0.97, 3.38) |
| - MI                          | 2 (0.6%)            | 0.179   | 0.124             | 4.79 (0.65, 35.20) |
| - Asystoly                    | 5 (1.4%)            | 0.588   | 0.997             | 0.00 (0.00, ∞)    |
| - Pericarditis                | 1 (0.3%)            | 1.000   | 0.997             | 0.00 (0.00, ∞)    |
| - Other                       | 5 (1.4%)            | 0.003   | 0.003             | 6.09 (1.86, 19.90) |
| Other complications           |                     |         |                   |                   |
| - Delirium                    | 42 (11.8)           | 0.000   | 0.001             | 2.63 (1.48, 4.66) |
| - JJS related***              | 26 (7.3)            | 0.120   | 0.141             | 1.76 (0.83, 3.72) |
| - UTI/retention               | 10 (2.8)            | 0.493   | 0.398             | 1.67 (0.51, 5.52) |
| - Trombo-embolic              | 8 (2.2)             | 1.000   | 0.965             | 0.97 (0.20, 4.67) |
| - CVA                         | 3 (0.8)             | 0.261   | 0.250             | 2.91 (0.47, 18.04) |
| Total complication rate       | 260 (72.8)          | 0.180   | 0.228             | 1.42 (0.80, 2.51) |
| Technical complications       |                     |         |                   |                   |
| - Reintervention              | 88 (24.6)           | 0.816   | 0.895             | 1.04 (0.61, 1.77) |
| Clinical complications        | 249 (69.7)          | 0.215   | 0.273             | 1.35 (0.79, 2.33) |
| Reintervention                | 114 (31.9)          | 0.355   | 0.425             | 1.22 (0.75, 1.98) |
| Reoperation                   | 78 (21.9)           | 0.416   | 0.350             | 0.75 (0.41, 1.37) |
| Radiologic reintervention     | 48 (13.4)           | 0.256   | 0.253             | 0.63 (0.29, 1.39) |
| Endoscopic reintervention Re-intubation | 47 (13.2) | 0.095   | 0.087             | 1.70 (0.93, 3.12) |
| ICU LOS (days)                |                     |         |                   |                   |
| - Median/IQR                  | 2 (3)               | 0.305   |                   |                   |
| ICU readmission               | 68 (19.0%)          | 0.991   | 0.854             | 0.95 (0.52, 1.72) |
| Hospital LOS (days)           |                     |         |                   |                   |
| - Median/IQR                  | 11 (11)             | 0.010   |                   |                   |
| Hospital LOS > 21 days        | 81 (22.7)           | 0.085   | 0.112             | 1.52 (0.91, 2.54) |
| Hospital Readmission          | 58 (16.2%)          | 0.705   | 0.561             | 0.82 (0.43, 1.59) |

*p value adjusted for ASA and CCI score after binomial logistic regression analysis

**Younger group N = 128 and elderly group N = 39

***Jejunostomy-related complications
Discussion

This study shows that the incidence of overall and severe complications (CD > 3) in this highly selected group of elderly patients undergoing Ivor Lewis TMIE is not higher than in younger patients. However, the incidence of cardiac complications and delirium were higher in the elderly group and hospital LOS was longer. Overall, this study supports the hypothesis that Ivor Lewis TMIE can be safely performed in selected elderly patients. Age alone should therefore not be a reason to withhold Ivor Lewis TMIE from patients.

The strengths of this study are, that this is one of the few studies investigating the influence of age on postoperative morbidity in a large multicenter outcome database and that this study specifically included patients undergoing Ivor-Lewis TMIE. In addition, we reported on a broad range of postoperative outcomes.

Limitations of this study are its retrospective character and the fact that a relatively small number of elderly patients were included compared to younger patients, limiting statistical power. In addition, the cohort of elderly patients in our study is a very selected group, representing the healthiest patients in their population, which is also underlined by the limited difference in baseline comorbidity between elderly and younger patients. Unfortunately, none of the participating hospitals used objective and specified criteria for selecting the elderly patients for TMIE as well as the younger patients and, therefore, we were unable to determine what characteristics these patients were selected on, and what characteristics lead to other definitive, non-surgical decisions.

Table 4 Mortality and survival

| Patients | Patients | $p$ value | Adjusted $p$ value* | Odds (95%-BI) |
|----------|----------|-----------|---------------------|---------------|
| < 75 years | $N = 357$ (%) | $\geq 75$ years | $N = 89$ (%) | | |
| In-hospital mortality | 11 (3.1) | 4 (3.4) | 0.513 | 0.591 | 1.38 (0.43, 4.48) |
| 30-day mortality | 10 (2.8) | 2 (2.2) | 1.000 | 0.699 | 0.74 (0.16, 3.46) |
| 90-day mortality | 18 (5.0) | 8 (9.0) | 0.155 | 0.208 | 1.75 (0.73, 4.20) |
| 1-year survival | 278 (77.9) | 68 (76.4) | 0.767 | 0.937 | 1.02 (0.59, 1.78) |
| 2-year survival* | 156 (54.5) | 43 (57.3) | 0.666 | 0.585 | 0.87 (0.52, 1.45) |

*Patients < 75 years old $N = 286$; patients $\geq 75$ years old $N = 75$

Fig. 1 Two-year survival.
Presented is an uncorrected Kaplan-Meier curve with a $p$ value in the middle as the result from log-rank testing. The numbers-at-risk-table is presented below the curve.
treatment. Some elderly patients, initially deemed fit for surgery, may had to drop out before operation, because of toxicity side effects caused by the neoadjuvant chemoradiotherapy regimen. Unfortunately, we were unable to calculate the drop-out rates for both groups because data on drop-outs is not included in the surgical database. However, since drop-out rates after neoadjuvant chemoradiotherapy have been shown to be low in general (2–8%), it is unlikely that these drop-out rates significantly influenced our results. More research is needed to investigate what criteria should be used for objectively selecting patients for curative esophageal surgery.

Studies on the influence of age in patients undergoing open esophagectomy show conflicting results. While some studies reported a higher incidence of non-surgical complications and higher mortality in the elderly group,6, 7, 20 other studies showed no difference in complications or mortality between the younger and elderly age groups.8, 9 For minimally invasive esophagectomy, a previous single-center study with 57 patients showed no significant difference in adverse events, length of stay, or mortality and which is grossly in line with the present study.21 Elderly patients may specifically benefit from minimally invasive esophagectomy, since it is associated with less post-operative morbidity compared to open esophagectomy.10, 11

The incidence of anastomotic leakage in the current study did not significantly differ between groups, but was higher than observed in previous studies.21–24 This may be attributed to the fact that, in the present study, all diagnosed anastomotic leaks were included, while others only reported anastomotic leaks requiring surgery representing only ECCG grade III leakages.22 The low percentage of ECCG grade III leakage as reported in the latter study (4.3%) was, however, comparable with our study (6.5%). Furthermore, the learning curve of minimally invasive surgical techniques may have played a role during the study period.25, 26

An important factor in the preoperative assessment of elderly patients is the presence of comorbidities, which have a large impact on the development of postoperative complications and overall survival after esophagectomy.27 This underlines the importance of assessing each potential candidate individually. In our study, the elderly group did not show a difference in comorbidities or ASA score compared with the younger group, which might be the result of the selection process. Although a longer hospital length of stay and a higher incidence of cardiac complications and delirium occurred in the elderly group, this observation did not result in a higher incidence of reinterventions, mortality, or impaired survival—which is in line with other studies. Delirium, however, has a substantial negative impact on hospital length of stay, quality of life, and costs.30 It also increases the risk for institutionalization in a nursing home and dementia.31 However, the incidence still might be an underestimation, since delirium is often underdiagnosed.32 Several studies showed a positive effect on the incidence of postoperative delirium with the help of special hospital programs and preoperative screening.33, 34 One randomized trial showed that “geriatrics consultation reduced delirium by over one-third” adding to the argument that active participation of a geriatrician in the perioperative care process could be beneficial when dealing with elderly patients undergoing esophagectomy.

Conclusion

Ivor Lewis TMIE can be safely performed in selected patients aged ≥75 years, without increasing severe complications or decreasing survival. Advanced age alone should not be a reason to withhold Ivor Lewis TMIE from patients. More research is needed to investigate what criteria should be used for selecting and preparing elderly patients with curable esophageal cancer for minimally invasive esophageal surgery.

Author Contributions Substantial contributions to the conception or design of the work: All authors, listed under the title of the article. Acquisition, analysis or interpretation of data for the work: Frans van Workum, Jolijn van der Maas, and Nikolaj S. Baranov.

Drafting the work or revising it critically for important intellectual content: All authors, listed under the title of the article.

Final approval of the version to be published: All authors, listed under the title of the article.

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All authors, listed under the title of the article.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Torre LA, Siegel RL, Ward EM, Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiol Biomarkers Prev 2016;25:16–27. doi:https://doi.org/10.1158/1055-9965.EPI-15-0578.
2. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074–84. doi:https://doi.org/10.1056/NEJMoa1112088.
3. Cunningham D, Allum WH, Stening SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20. doi:https://doi.org/10.1056/NEJMoa055531.
4. Koppert LB, Janssen-Heinjens MLG, Louwman MWJ, Lemmens VEP, Wijnhoven BPL, Timals HW, et al. Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study. Eur J Gastroenterol Hepatol 2004;16:681–8.
5. Janssen-Heinjens MLG, Houterman S, Lemmens VEP, Louwman MWJ, Maas HAAM, Coebergh JW. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-
based approach. Crit Rev Oncol Hematol 2005;55:231–40. doi: https://doi.org/10.1016/j.critrevonc.2005.04.008.

6. Cjjs TM, Verhoef C, Steyerberg EW, Koppert LB, Tran TCK, Wijnhov BPL, et al. Outcome of esophagectomy for cancer in elderly patients. Ann Thorac Surg 2010;90:900–7. doi:https://doi.org/10.1097/SLA.0b013e3181f5db60.

7. Tapias LF, Muniappan A, Wright CD, Gaisseg HA, Wain JC, Morse CR, et al. Short and long-term outcomes after esophagectomy for cancer in elderly patients. Ann Thorac Surg 2013;95:1741–8. doi:https://doi.org/10.1097/SLA.0b013e318273494f.

8. Alibakhshi A, Amianin A, Minzari R, Jahanari Y, Dasthi H, Karimian F. The effect of age on the outcome of esophageal cancer surgery. Ann Thorac Med 2009;4:71–4. doi:https://doi.org/10.1007/s11605-016-3083-5.

9. Alibakhshi A, Amianin A, Minzari R, Jahanari Y, Dasthi H, Karimian F. The effect of age on the outcome of esophageal cancer surgery. Ann Thorac Med 2009;4:71–4. doi:https://doi.org/10.1007/s11605-016-3083-5.

10. Biere SSAY, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet Lond Engl 2012;379:1887–92. doi:https://doi.org/10.1016/S0140-6736(12)60516-9.

11. Mariette C, Meunier B, PdT D, Dalban C, Collet D, Thomas P-A, et al. Hybrid minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicenter, open-label, randomized phase III controlled trial, the MIRO trial. American Society of Clinical Oncology; 2015.

12. van Workum F, Berkelmans GH, Klarenbeek BR, Nieuwenhuijzen GAP, Luyer MDP, et al. Internal and External Validation of a multi-institutional study (YSURG1401). BMC Surg 2017;17:92. doi:https://doi.org/10.1186/s12893-017-0229-7.

13. Tapias LF, Muniappan A, Wright CD, Gaisseg HA, Wain JC, Morse CR, et al. Outcome of patients with oesophageal cancer: a multicentre, open-label, randomized phase III controlled trial, the MIRO trial. American Society of Clinical Oncology; 2015.

14. Fujii S, Tsukamoto M, Fukushima Y, Shimada R, Okamoto K, Weijs TJ, Seesing MFJ, van Rossum PSN, Koëter M, van der Sluis S, et al. Robotic assisted Ivor Lewis totally minimally invasive esophagectomy in the elderly: results of current surgical management. Ann Surg 1998;227:357–64.

15. Abbott A, Shridhar R, Hoffe S, Almhamm K, Doepker M, Saeed N, et al. Robotic assisted Ivor Lewis esophagectomy in the elderly patient. J Gastrointest Oncol 2015;6:31–8. doi:https://doi.org/10.3978/j.issn.2078-6891.2014.0495.

16. Lukeitch JD, Punnathur A, Awais O, Levy RM, Keeley S, Shende M, et al. Outcomes after minimally invasive esophagectomy: review of over 1000 patients. Ann Surg 2012;256:95–103. doi:https://doi.org/10.1097/SLA.0b013e3182590603.

17. Miyata H, Yamasaki M, Makino T, Miyazaki Y, Takahashi T, Kurokawa Y, et al. Clinical Outcome of Esophagectomy in Elderly Patients With and Without Neoadjuvant Therapy for Thoracic Esophageal Cancer. Ann Surg Oncol 2015;22 Suppl 3: S794–801. doi:https://doi.org/10.1245/s10434-015-4769-8.

18. Brown AM, Pucci MJ, Berger AC, Tatarian T, Evans NR, Rosato EL, et al. A standardized comparison of peri-operative complications after minimally invasive esophagectomy: Ivor Lewis versus McKeown. Surg Endosc 2018;32:204–11. doi:https://doi.org/10.1007/s00464-017-5660-4.

19. Koppert LB, Lemmens VEPF, Coebergh JWJ, Steyerberg EW, Wijnhov BPL, Tilanus HW, et al. Impact of age and comorbidity on surgical resection rate and survival in patients with oesophageal and gastric cancer. Br J Surg 2012;99:1693–700. doi:https://doi.org/10.1002/bjs.8952.

20. Markar SR, Karthikesalingam A, Thurumruh S, Ho A, Muallem L, Low DE. Systematic review and pooled analysis assessing the association between elderly age and outcome following surgical resection of esophageal malignancy. Dis Esophagus Off J Int Soc Dis Esophagus 2013;26:250–62. doi:https://doi.org/10.1111/j.1442-2050.2012.01353.x.

21. Takeuchi M, Takeuchi H, Fujisawa D, Miyajima K, Yoshikura K, Hashiguchi S, et al. Incidence and risk factors of postoperative delirium in patients with esophageal cancer. Ann Surg Oncol 2012;19:3963–70. doi:https://doi.org/10.1245/s10434-012-2432-1.

22. Markar SR, Smith IA, Karthikesalingam A, Low DE. The clinical and economic costs of delirium after surgical resection for esophageal malignancy. Ann Surg 2013;258:77–81. doi:https://doi.org/10.1097/SLA.0b013e31828545e1.

23. Witlox J, Eurelings LSM, de Jonghe JFM, Kalsivaart KJ, Eikenboom PB, van Gool WA. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 2010;304:443–51. doi:https://doi.org/10.1001/jama.2010.1013.

24. Fong TG, Tuilebaev SR, Inouye SK. Delirium in elderly adults: diagnosis, prevention and treatment. Nat Rev Neurol 2009;5:210–20. doi:https://doi.org/10.1038/nrneurol.2009.22.

25. Chen CC-H, Li H-C, Liang J-T, Lai J-R, Parmarmono JDT, Yang Y-T, et al. Effect of a Modified Hospital Elder Life Program on Delirium and Length of Hospital Stay in Patients Undergoing Abdominal Surgery: A Cluster Randomized Clinical Trial. JAMA Surg 2017;152:827–34. doi:https://doi.org/10.1001/jamasurg.2017.1083.

26. Wilt J, Tricco AC, Talbot-Hamon C, Pham B, Rios P, Grudniewicz A, et al. Identifying older adults at risk of harm following elective surgery: a systematic review and meta-analysis. BMC Med 2018;16:2. doi:https://doi.org/10.1186/s12916-017-0986-2.